ImmunityBio Inc. (IBRX)
NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IBRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.40B
- EPS (TTM)
- -$1.06
- Dividend yield
- None
- 52-week range
- 1.95 – 12.43
- Day range
- 6.00 – 6.53
- Volume / Avg
- 10.57M / 12.97M
- Beta
- —
- Shares outstanding
- 1.06B
52-week range
IBRX stock today
On Nov 20, IBRX ended the session at $6.02, shedding $0.55 (8.37%), versus the S&P 500's 3.70% decline. Shares are 51.6% below their 52-week high of $12.43, set on Feb 25, 2026 and 208.7% above the 52-week low of $1.95, in the middle of the past year's range. IBRX is up 204.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 189.4%.
ImmunityBio has posted a net loss over the last twelve months (EPS of -$1.06), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About ImmunityBio
Company profileImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Richard Gerald Adcock
- Headquarters
- San Diego, CA
- Employees
- 684
- IPO year
- 2015
- Website
- immunitybio.com
Financial highlights
Full financialsIn fiscal 2025, ImmunityBio generated $113.3 million in revenue, up 668.3% from fiscal 2024, its 3rd consecutive year of revenue growth. ImmunityBio reported a net loss of $351.4 million, compared with a loss of $413.6 million a year earlier. Gross margin was 99.3% (down from 100.0%) and operating margin -226.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $113.29M | $14.74M | $622.00K | $240.00K | $934.00K |
| Growth | +668.31% | +2270.58% | +159.17% | -74.30% | +54.38% |
| Net income | $-351.40M | $-413.56M | $-583.20M | $-416.57M | $-346.79M |
| EPS (diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$14.25+136.71%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.10 vs $-0.08
- Surprise
- -25.00%
IBRX news
All IBRX news- IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%NasdaqIBRX, HALO, TGTX, AMRX
- Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?Nasdaq
- ImmunityBio, Inc. Reports Q3 2026 Net Product Revenue of $48.7 Million and FDA Label Expansion for ANKTIVANasdaq
- ImmunityBio, Inc. Announces ANKTIVA Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 TrialNasdaq
- ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue EstimatesNasdaqIBRX, BHST
- ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 MillionBusiness Wire
- Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock DownNasdaqAGEN, TGTX, AMRX, IBRX
- SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales DeclineNasdaqSRPT, AMRX, IBRX
ImmunityBio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KODKodiak Sciences Inc | 97.17 | -0.75% | $6.35B | vs IBRX |
| IMVTImmunovant Inc. | 31.77 | -2.31% | $6.57B | vs IBRX |
| SRRKScholar Rock Holding Corporation | 48.13 | -4.45% | $5.87B | vs IBRX |
| TWSTTwist Bioscience Corporation | 103.32 | -7.44% | $7.04B | vs IBRX |
| CGONCG Oncology Inc. | 79.47 | -2.97% | $7.10B | vs IBRX |
| ADPTAdaptive Biotechnologies Corporation | 27.93 | -0.43% | $4.52B | vs IBRX |
| PCVXVaxcyte Inc. | 55.39 | -5.09% | $8.77B | vs IBRX |
| CRSPCRISPR Therapeutics AG | 39.10 | +0.44% | $3.79B | vs IBRX |
Indexes, lists and sector
ImmunityBio stock FAQ
What is ImmunityBio's stock price today?
IBRX last traded at $6.02 as of Nov 20, 4:00 PM EST, down 8.37% on the day. Prices are delayed at least 15 minutes.
Who is ImmunityBio's CEO?
Mr. Richard Gerald Adcock is the chief executive officer of ImmunityBio Inc., which has about 684 employees.
What is the IBRX 52-week high?
The 52-week high for IBRX is $12.43 and the 52-week low is $1.95. The stock is currently 51.6% below its high.